Highlights and Quick Summary
- Research and Development (R&D) Expenses Growth for the quarter ending March 31, 2022 was -0.37% (a -102.7% decrease compared to previous quarter)
- Year-over-year quarterly Research and Development (R&D) Expenses Growth decreased by -100.23%
- Annual Research and Development (R&D) Expenses Growth for 2021 was 71.19% (a -256.53% decrease from previous year)
- Annual Research and Development (R&D) Expenses Growth for 2020 was -45.48% (a -210.93% decrease from previous year)
- Annual Research and Development (R&D) Expenses Growth for 2019 was 41.0% (a -40.97% decrease from previous year)
- Twelve month Research and Development (R&D) Expenses Growth ending March 31, 2022 was 47.27% (a -32.62% decrease compared to previous quarter)
- Twelve month trailing Research and Development (R&D) Expenses Growth increased by 677.47% year-over-year
Trailing Research and Development (R&D) Expenses Growth for the last four month:
| 31 Mar '22 | 31 Dec '21 | 30 Sep '21 | 30 Jun '21 |
|---|---|---|---|
| 47.27% | 70.15% | 52.12% | 6.08% |
Visit stockrow.com/ALNA
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Research and Development (R&D) Expenses Growth of Allena Pharmaceuticals, Inc.
Most recent Research and Development (R&D) Expenses Growthof ALNA including historical data for past 10 years.Interactive Chart of Research and Development (R&D) Expenses Growth of Allena Pharmaceuticals, Inc.
Allena Pharmaceuticals, Inc. Research and Development (R&D) Expenses Growth for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2022 | -0.37% | – | – | – | – |
| 2021 | 13.7% | 80.29% | 162.87% | 67.61% | 71.19% |
| 2020 | -20.49% | -54.17% | -55.66% | -49.1% | -45.48% |
| 2019 | 19.98% | 47.7% | 46.57% | 53.9% | 41.0% |
| 2018 | 52.68% | 148.08% | 69.46% | 36.31% | 69.46% |
| 2017 | -9.54% | -59.69% | -40.99% | -26.64% | -22.8% |
| 2016 | – | – | – | 10.54% | 74.2% |
| 2015 | – | – | – | – | -42.6% |
Business Profile of Allena Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.